MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Aromatase inhibitors better than tamoxifen

Breast cancer treatment Breast cancer main Breast cancer news  

Aromatase inhibitors better than tamoxifen : Information from MedicineWorld.Org
Aromatase inhibitors better than tamoxifen
  Aromatase inhibitors clearly outperforms Tamoxifen in the adjuvant treatment of hormone receptor positive breast cancer.

     As per new data presented at San Antonio breast cancer conferences (2004) Arimidex (Anastrazole) is better than Tamoxifen for the adjuvant treatment of hormone receptor positive breast cancer. Another study presented at the same symposium showed that switching to another member of the family, Aromasin (Exemstane), after two years of tamoxifen therapy was substantially more effective than sticking to tamoxifen for the normal five-year course of therapy.

      This study in which 5,000 patients participated has shown that women who switched to exemstane after two years had a 30% reduction in recurrence over the three years of the study and a 54% reduction in cancer in the second breast, compared to women who continued on Tamoxifen. Exemstane was clearly shown to be superior.

      A third study in which 3,000 women participated showed that switching from tamoxifen to anastrozole after two or three years reduced the risk of recurrence by 40%.

Results reported last year with a third member of the family of aromatase inhibitor, lotrezole (trade named Femara), showed that giving it to women after they had completed five years of therapy with Tamoxifen, at which point that drug is no longer effective, could reduce tumor recurrence over the next five years by 43%.

 
 
 
Related Resources
  • Brca research
  • Brca
  • Brca1 and brca2
  • Epidemiology
  • Breast Main
  • My risk
  • Risk factors
  • Breast cancer stats
  • Symptoms
  • Bisphosphonates
  • Chemodrugs: breast
  • Chemotherapy
  • Doxorubicin
  • Hormone therapy
  • Monoclonal
  • Radiationtherapy
  • Recurrent
  • Rx by stage
  • Surgery
  • Treatment


  •  
     
    epidemiology
     Breast cancer
     Colon cancer
     Prostate cancer
     Ovarian cancer
     Esophageal cancer
     Bladder cancer
     Anal cancer
     Endometrial cancer
     Pancreatic cancer
     Cervical cancer
     Gastric cancer
     Cancer News